OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

1 Projects | 1 Researchers | $4,556,150 Invested

2022

Cognito Therapeutics

Ralph Kern

Cognito Therapeutics - A novel digital therapeutic for neurodegenerative diseases

  • Funding Amount: $4,556,150
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Neuronal Degeneration
  • Status: Active